GlaxoSmithKline plc's (GSK) "Buy" Rating Reaffirmed at Beaufort Securities

GlaxoSmithKline plc's (GSK) "Buy" Rating Reaffirmed at Beaufort Securities


's stock had its "buy" rating reissued by research analysts at Beaufort Securities in a research note issued to investors on Friday. They currently have a GBX 1,750 target price on the stock.



from Biotech News